Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Pittsburgh, April 03, 2017 -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced that the company has been selected to present at the annual Future Leaders in the Biotech Industry conference hosted by BioCentury. Kenneth I. Moch, president & CEO of Cognition will present an update on corporate milestones and development status of CT1812, the company’s lead candidate for the treatment of Alzheimer’s disease. The presentation will take place on April 7th at 2:30 p.m. Eastern Time at the Millennium Broadway Hotel & Conference Center. For more information or to request a one-on-one meeting, please refer to BioCentury’s website.
About CT1812
CT1812 is a proprietary first-in-class, orally available small molecule that displaces bound beta amyloid oligomers and inhibits binding of Aβ oligomers to the receptor complex. The molecule was designed by Cognition’s scientific team, led by Susan Catalano, Ph.D., to target, displace and clear the toxic beta amyloid oligomers that cause Alzheimer’s disease. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss.In Cognition’s ongoing Study COG0102, patients with mild-to-moderate Alzheimer’s disease are being randomized to one of two doses of CT1812 (280mg patients or 560mg) or placebo, and dosed for 28 days to help evaluate the safety, tolerability and pharmacokinetic profile of CT1812. Cognition has previously conducted single and multiple ascending dose studies in 94 healthy volunteers, 74 of whom received CT1812. Study COG0102 is supported in part under Award Number RF1AG054176 from the National Institute on Aging of the National Institutes of Health.
About Cognition Therapeutics, Inc.
Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer’s disease and potentially other neurocognitive disorders. Additional information about Cognition may be found online at http://www.cogrx.com.
Hank Safferstein SVP, Cognition Therapeutics [email protected] Aline Sherwood Scienta Communications [email protected]
